一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Sigvotatug Vedotin；Pembrolizumab，当前状态为招募中。登记地点显示中国合肥、北京、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sigvotatug Vedotin；Pembrolizumab · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Cancer Hospital · 合肥
- Beijing Cancer hospital · 北京
- Beijing Chest Hospital,Capital Medical University · 北京
- Fujian Cancer Hospital · 福州
- Nanfang Hospital of Southern Medical University · 广州
- Huizhou Central People's Hospital · 惠州
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Harbin Medical University Cancer Hospital · 哈尔滨
- The First Affiliated Hospital of Henan University of Science &Technology · 洛阳
- Henan Cancer Hospital · 郑州
- Wuhan Union Hospital Cancer Center · 武汉
- Hubei Cancer Hospital · 武汉
- Hunan Cancer Hospital · 长沙
- The First People's Hospital of Changzhou · 常州
- Jiangsu Province Hospital · 南京
- The Affiliated Hospital of Xuzhou Medical College · 徐州
- The First Affiliated Hospital of Nanchang University · 南昌
- Jilin Province Tumor Hospital · 长春
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- Jinan Central Hospital · 济南
- Shandong Cancer Hospital · 济南
- LinYi Cancer Hospital · 临沂
- Shanghai Chest Hospital · 上海
- Fudan University Shanghai Cancer Center · 上海
- Sichuan Cancer hospital · 成都
- West China Hospital, Sichuan University · 成都
- Tianjin Medical University General Hospital · 天津
- Yunnan Province Cancer Hospital · 昆明
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine · 杭州
- Taizhou Hospital of Zhejiang Province · 台州
- The First Affiliated Hospital of Wenzhou Medical University · 温州
公开的入选条件
- 1. Participants must meet the following criteria:
- 1. Have pathologically confirmed Stage IIIB or IIIC NSCLC and not be a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCLC per the AJCC Staging Manual (Version 8.0) and the UICC Staging System (Eighth edition).
- 2. Participants with known AGAs including EGFR, ALK, ROS1, NTRK, BRAF, RET, and MET, for which there are approved and available first-line therapies per local SOC are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for partici
- 3. Participants with large cell neuroendocrine carcinoma are excluded.
- 4. Must be an appropriate candidate for treatment with pembrolizumab monotherapy per local guidelines.
- 2. Tumor has PD-L1 expression in ≥50% of tumor cells (TPS ≥50%) as determined by local testing.
- 3. Measurable disease based on RECIST v1.1 per investigator.
- 4. Resolution of acute effects of any prior therapy to either baseline severity or NCI CTCAE Grade 1 or less (except for AEs not constituting a safety risk in the investigator's judgment), unless otherwise excluded.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06758401；登记信息更新于 2026-09-25。